المؤلفون: Hozefa A. Divan, Marisa A. Bittoni, Ashok Krishna, David P. Carbone

المصدر: BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)

مصطلحات موضوعية: Non-small cell lung cancer, PD-1 inhibitors, PD-L1 inhibitors, Real-world evidence, Patient characteristics, Observational study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/aa594b592c1d4e0e9a2a1f1be367ad4aTest

المؤلفون: Huanhuan Bi, Dunqiang Ren, Yuting Xiao, Yinxue Zhou, Bingqian Yi, Weizhong Han, Yanmei Shao, Jingluan Wang, Chunling Zhang, Hongmei Wang

المصدر: Thoracic Cancer, Vol 15, Iss 7, Pp 559-569 (2024)

مصطلحات موضوعية: extensive‐stage small cell lung cancer, immune‐related adverse events, neutrophil‐to‐lymphocyte ratio, overall survival, PD‐L1 inhibitors, progression‐free survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1759-7706Test; https://doaj.org/toc/1759-7714Test

الوصول الحر: https://doaj.org/article/af229f864f134f719caa6fecfdf24090Test

المؤلفون: Sisi Zhang, Jing Tian, Xinwei Wang, Chengxin Liu

المصدر: BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-10 (2023)

مصطلحات موضوعية: Immune checkpoint inhibitors, PD-L1 inhibitors, Immunotherapy, Proton pump inhibitors, Progression free survival, Overall survival, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2466Test

الوصول الحر: https://doaj.org/article/2296cf0a943a49c8bcd8c24d56aeef74Test

المؤلفون: Daniel Huff, Shannon Fortin Ensign, Margaret S. Ryan, Jeanne Palmer, Javier Munoz

المصدر: Journal of Immunotherapy and Precision Oncology, Vol 6, Iss 4, Pp 198-202 (2023)

مصطلحات موضوعية: case report, histiocytic sarcoma, pd-l1 inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2666-2345Test; https://doaj.org/toc/2590-017XTest

الوصول الحر: https://doaj.org/article/0be91353727144ef8f1dab31b961fef6Test

المؤلفون: Ting Yan, Lun Yu, Jiwen Zhang, Yun Chen, Yilan Fu, Jingyi Tang, Dehua Liao

المصدر: Frontiers in Immunology, Vol 15 (2024)

مصطلحات موضوعية: PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, immune-related adverse events, ICIs, ICIS, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1292122/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/97d49991bfc145c8ba2501718e897179Test

المؤلفون: Songfei Han, Cuishan Guo, Zixuan Song, Ling Ouyang, Yizi Wang

المصدر: Frontiers in Pharmacology, Vol 14 (2023)

مصطلحات موضوعية: endometrial cancer, PD-1 inhibitors, PD-L1 inhibitors, immunity inhibitor, gynecological tumor, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2023.1330877/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/48d3528cd63943058f17cb2c199114c3Test

المؤلفون: Jianfeng Peng, Lemeng Zhang, Liping Wang, Hui Feng, Dongmei Yao, Rui Meng, Xiaomei Liu, Xiaohua Li, Ningbo Liu, Bingxu Tan, Zhaoqin Huang, Shanshan Li, Xiangjiao Meng

المصدر: Radiation Oncology, Vol 18, Iss 1, Pp 1-12 (2023)

مصطلحات موضوعية: Extensive stage small cell lung cancer, PD-L1 inhibitors, Thoracic radiotherapy, Survival, Toxicity, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1748-717XTest

الوصول الحر: https://doaj.org/article/a73b69be6b0e46688ceb02b6fe9f4456Test

المؤلفون: Jingyuan Xie, Mo Chen, Hedong Han, Ke Xu, Guihuan Qiu, Xinqing Lin, Yong Song, Jinjun Ye, Tangfeng Lv, Ping Zhan

المصدر: Thoracic Cancer, Vol 14, Iss 15, Pp 1327-1338 (2023)

مصطلحات موضوعية: extensive‐stage SCLC, PD‐1 inhibitors, PD‐L1 inhibitors, propensity score‐matched analysis, risk factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1759-7706Test; https://doaj.org/toc/1759-7714Test

الوصول الحر: https://doaj.org/article/3d4735eda4554e069c8c2f261ae127c2Test

المؤلفون: Amine Bouhamama, Benjamin Leporq, Khuram Faraz, Jean-Philippe Foy, Maxime Boussageon, Maurice Pérol, Sandra Ortiz-Cuaran, François Ghiringhelli, Pierre Saintigny, Olivier Beuf, Frank Pilleul

المصدر: Frontiers in Radiology, Vol 3 (2023)

مصطلحات موضوعية: radiomics, NSCLC, immunotherapy, PD-L1 inhibitors, transcriptomics, Medical physics. Medical radiology. Nuclear medicine, R895-920

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fradi.2023.1168448/fullTest; https://doaj.org/toc/2673-8740Test

الوصول الحر: https://doaj.org/article/d51f1dbd8d0c49318bdb70da0d9c489cTest

المؤلفون: S. V. Yugay, К. V. Dehanova, I. V. Rikov, М. F. Balluzek, С. В. Югай, К. В. Деханова, И. В. Рыков, М. Ф. Баллюзек

المصدر: Malignant tumours; Том 13, № 1 (2023); 24-29 ; Злокачественные опухоли; Том 13, № 1 (2023); 24-29 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: МРТ сердца, PD-L1 inhibitors, focal myocarditis, autoimmune thrombocytopenia, cardiac MRI, PD-L1 ингибиторы, фокальный миокардит, аутоиммунная тромбоцитопения

وصف الملف: application/pdf

العلاقة: https://www.malignanttumors.org/jour/article/view/1101/778Test; Hryniewicki, A. T., Wang, C., Shatsky, R. A., & Coyne, C. J. (2018). Management of Immune Checkpoint Inhibitor Toxicities : A Review and Clinical Guideline for Emergency Physicians. Journal of Emergency Medicine, 55 (4), 489–502. https://doi.org/10.1016/j.jemermed.2018.07.005Test.; Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, (2017). Management of toxicities from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28 (Supplement 4), iv119–iv142. https://doi.org/10.1093/annonc/mdx225Test.; Gürdoğan M, Yalta K. Myocarditis associated with immune checkpoint inhibitors : Practical considerations in diagnosis and management. Anatol J Cardiol. 2020; 24 (2) : 68–75. doi:10.14744/AnatolJCardiol.2020.; Zhang L., Awadalla M., Mahmood S.S., Nohria A., Hassan M.Z.O., Thuny F., et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020; 41 : 1733–43.; Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. National Comprehensive Cancer Network. J ClinOncol. 2018 Jun 10; 36 (17) : 1714–1768.; Ahmad, S., Lewis, M., Corrie, P., &Iddawela, M. (2012). Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. Journal of Oncology Pharmacy Practice, 18 (2), 287–292. https://doi.org/10.1177/107815521141100Test.; Le Roy, A., Kempf, E., Ackermann, F., Routier, E., Robert, C., Turpin, A., Marabelle, A., Mateus, C., Michot, J. M., &Lambotte, O. (2016). Two cases of immune thrombocytopenia associated with pembrolizumab. European Journal of Cancer, 54 (August 2014), 172–174. https://doi.org/10.1016/j.ejca.2015.10.073Test.; Mouri, A., Kaira, K., Shiono, A., Miura, Y., &Kagamu, H. (2020). Severe Thrombocytopenia Associated with Pembrolizumab in Patients with Non-small Cell Lung Cancer (NSCLC) : A case report and literature review. In Vivo, 34 (2), 877–880. https://doi.org/10.21873/invivo.11852Test.; Song, P., & Zhang, L. (2019). Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab. European Journal of Cancer, 121, 4–6. https://doi.org/10.1016/j.ejca.2019.08.003Test.; Shiuan, E., Beckermann, K. E., Ozgun, A., Kelly, C., McKean, M., McQuade, J., Thompson, M. A., Puzanov, I., Greer, J. P., Rapisuwon, S., Postow, M., Davies, M. A., Eroglu, Z., & Johnson, D. (2017). Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. Journal for ImmunoTherapy of Cancer, 5 (1), 4–9. https://doi.org/10.1186/s40425-017-0210-0Test.; Chaturvedi, S., Arnold, D. M., & McCrae, K. R. (2018). Splenectomy for immune thrombocytopenia : Down but not out. Blood, 131 (11), 1172–1182. https://doi.org/10.1182/blood-2017-09-74235311Test.; Neunert, C., Lim, W., Crowther, M., Cohen, A., Solberg, L., &Crowther, M. A. (2011). The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 117 (16), 4190–4207. https://doi.org/10.1182/blood-2010-08-302984Test.; Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., Becker, J. R., Slosky, D. A., Phillips, E. J., Pilkinton, M. A., Craig-Owens, L ., Kola, N., Plautz, G., Reshef, D. S., Deutsch, J. S., Moslehi, J. J. (2016). Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 375 (18), 1749–1755. https://doi.org/10.1056/nejmoa1609214Test.; Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., Atkins, M. B., Ernstoff, M. S., Reardon, D. A., Puzanov, I., Kudchadkar, R. R., Thomas, R. P., Tarhini, A., Pavlick, A. C., Jiang, J., Margolin, K. (2018). Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New Eng J Med, 379 (8), 722–730. https://doi.org/10.1056/nejmoa1805453Test.; Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L ., Margolin, K., Mitchell, A., Olencki, T., Pardoll, D. M., Reddy, S. A., … Cheever, M. A. (2016). PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New Engl J Med, 374 (26), 2542–2552. https://doi.org/10.1056/nejmoa1603702Test.; 41 : 1733–43; https://www.malignanttumors.org/jour/article/view/1101Test

الإتاحة: https://doi.org/10.18027/2224-5057-2023-13-1-24-29Test
https://doi.org/10.14744/AnatolJCardiol.2020Test
https://doi.org/10.1056/nejmoa1609214Test
https://doi.org/10.1056/nejmoa1805453Test
https://doi.org/10.1056/nejmoa1603702Test
https://www.malignanttumors.org/jour/article/view/1101Test